Stifel says Krystal needs robust start form growth; shares fall

Krystal Biotech

06/11/2023 19:02

** Shares of gene therapy developer Krystal Biotech  KRYS.O 
fall 13.5% to $105.99
    ** Brokerage Stifel says robust growth in co's patient start
forms will be needed for the shares' momentum to pick back up
    ** Says Krystal's Q3 revenue beat alone will not help
justify the current valuation
    ** Start forms enroll patients to a treatment or program 
    ** Co reports Q3 revenue of $8.6 mln vs analysts' average
estimate of $6.32 mln - LSEG data
    ** Including session's move, stock up ~32.7% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))